Incyte (INCY)
(Delayed Data from NSDQ)
$51.68 USD
+0.50 (0.98%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $51.76 +0.08 (0.15%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Price, Consensus and EPS Surprise
INCY 51.68 +0.50(0.98%)
Will INCY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for INCY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for INCY
The Zacks Analyst Blog Highlights Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals
Biotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
INCY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
Other News for INCY
Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Repare Therapeutics appoints Steven Stein to its board of directors
Incyte’s Strategic Acquisition and Promising Pipeline Secure Buy Rating
Incyte price target lowered by $10 at Argus, here's why
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)